Ticker

Analyst Price Targets — FBRX

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
July 28, 2026 7:34 amEtzer DaroutBarclays$77.00$76.50StreetInsider Barclays Downgrades Forte Biosciences Inc. (FBRX) to Equalweight
July 27, 2026 3:02 pmEvercore ISI$77.00$76.42TheFly Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
July 21, 2026 8:47 amBarclays$74.00$47.49TheFly Forte Biosciences initiated with an Overweight at Barclays
November 25, 2025 11:34 amEvercore ISI$65.00$19.06TheFly Forte Biosciences initiated with an Outperform at Evercore ISI

Latest News for FBRX

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx's portfolio of differentiated immunology medicines,…

GlobeNewsWire • Aug 27, 2026
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte Biosciences, Inc. (NasdaqCM: FBRX) to argenx SE (NasdaqGS: ARGX). Under the terms of the proposed transaction, shareholders of Forte will receive $77.00 in cash for each share of Forte that they own. KSF is seeking to…

Business Wire • Aug 11, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

Senate Trading Disclosures

NameTransaction DateTypeAssetAmountLink

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top